AstraZeneca gets some upbeat asthma data to back would-be IL-5 blockbuster – FierceBiotech

AstraZeneca gets some upbeat asthma data to back would-be IL-5 blockbuster
FierceBiotech
Benralizumab–an IL-5 antibody–reduced the rate of asthma exacerbations, hitting the primary endpoint in the trial, says AstraZeneca ($AZN). But the study flagged weak results for the low end of the doses used in the trial, with the top dose doing
AstraZeneca share price: Novel drug shows positive results for severe asthmaiNVEZZ
AstraZeneca's benralizumab succeeds in severe asthmaPharmaTimes

all 4 news articles »

View full post on asthma – Google News

Roche scores upbeat data for a personalized asthma drug with blockbuster hopes – FierceBiotech


Drug Discovery & Development

Roche scores upbeat data for a personalized asthma drug with blockbuster hopes
FierceBiotech
Roche's ($RHHBY) lebrikizumab significantly reduced the rate of asthma attacks in patients with a severe form of the disease, according to mid-stage trial results, lighting the way for a Phase III study on the novel, personalized treatment. The drug
Biologic May Tame Severe AsthmaMedPage Today
Roche drug cuts asthma attacks, improves lung function -studyReuters
Lebrikizumab Phase 2b Data Show Reduction of Asthma Attack RatesDrug Discovery & Development
PharmaTimes
all 12 news articles »

View full post on asthma – Google News

Boston Scientific Shows Upbeat Data – Daily Markets

Boston Scientific Shows Upbeat Data
Daily Markets
Leading medical devices player Boston Scientific (NYSE:BSX) presented positive data from the Research in Severe Asthma (RISA) trial at a conference in Amsterdam. It was observed that patients with severe refractory asthma, when treated with Alair
Boston Scientific begins enrolment for nerve stimulation trialZenopa

all 2 news articles »

View full post on asthma – Google News